Breaking space news, the latest updates on rocket launches, skywatching events and more! You are now subscribed Your newsletter sign-up was successful Want to add more newsletters? Delivered daily ...
Jan 14 (Reuters) - Structure Therapeutics' (GPCR.O), opens new tab CEO expects oral weight-loss pills to capture as much as half of the GLP-1 market by 2030, driven partly by pent-up demand from ...
The Pickaxe Expansion Mod introduces exciting new pickaxes, blocks, and resources to enhance your mining experience in Minecraft 1.12.2. Craft powerful new tools, gather rare materials, and dominate ...
Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...
Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top ...
Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...
Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...
A pill from Structure Therapeutics Inc. helped patients lose roughly as much weight as a rival treatment from Eli Lilly & Co., giving the startup an edge as it seeks to break into the highly ...
Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring Monday after the clinical-stage biopharmaceutical company reported positive topline data from a weight loss drug trial. The positive ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The South San Francisco biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results